checkAd

     168  0 Kommentare Tetra Bio-Pharma Provides an Update on Its Veterinary Ophthalmic Clinical Study with PPP003 - Seite 3

    For further information, please contact Tetra Bio-Pharma Inc.:

    Investor Contact:
    Bruce Mackle
    LifeSci Advisors LLC
    646-889-1200
    Tetrainvestors@LifeSciAdvisors.com           

    Lesen Sie auch

    Media Contact: 
    Andrew Mielach
    LifeSci Public Relations
    646-876-5868
    amielach@lifescipublicrelations.com

    Canada:
    Carol Levine 
    Energi PR 
    514-288-8500 ext. 226 
    carol.levine@energipr.com 


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Tetra Bio-Pharma Provides an Update on Its Veterinary Ophthalmic Clinical Study with PPP003 - Seite 3 Tetra’s sterile cannabinoid manufacturing facility fully validated and operationalTetra’s subsidiary, Panag Pharma, ready to initiate the treatment phase of clinical trial of PPP003 for treatment of eye pain OTTAWA, Jan. 28, 2020 (GLOBE NEWSWIRE) …